We envision personalized, efficient and clinically smart cardiac care that helps drive optimal outcomes throughout the patient journey. Our vision offers strategic and focused approach, addressing critical cardiac care needs and meeting better health outcomes, lower cost of care and improved patient and staff experience.
That is why the Philips Interventional Applications Platform — IntraSight — offers a comprehensive suite of clinically proven1-5 imaging, physiology and co-registration6 tools on a modern, secure platform. These best-in-class interventional tools allow you to see clearly beyond the angiogram and ultimately complete your view of the target vessel so you can make fast, informed clinical decisions to treat optimally. IntraSight’s intuitive user interface and simplified workflow contributes to an outstanding user experience in both Philips and non-Philips x-ray labs. IntraSight also helps optimize lab performance with its unique tableside touchscreen module that allows users to run an entire case within the sterile field. Note: IntraSight 7, iFR Co-registration and IVUS Co-registration are not available on IntraSight mobile platform.
Stay up-to-date and get informed about interventional cardiology topics. Or get in touch with our sales team.
the global gold standard among resting indices with a Class IA recommendation in the ACC/AHA/SCAI and ESC Guidelines.7,8
with the angiogram using iFR Co-registration, IVUS Co-registration and Tri-registration features*
to be run tableside without breaking scrub with the touch screen module
Built on a smart, applications-based platform that can scale to meet the evolving needs of your lab when new applications or modalities become available, without the need to purchase new hardware. Only Philips Interventional Applications Platform, IntraSight, offers best-in-class imaging and physiology tools with iFR, iFR Co-registration*, FFR, IVUS, IVUS Co-registration*, and Angio+*. With its modular architecture, IntraSight stays on top of latest advances and important security updates.
has clinically validated patient outcome data in the largest physiology studies ever conducted. No other resting index has patient outcome data to support its use.7,8
is “definitely beneficial” for patients,9 and resulted in a change of treatment plans 74% of the time.10
First interventional platform to run on Microsoft Windows 10, providing the latest data encryption and advanced protection against cybersecurity threats. Usernames/passwords controlled by administrator and system auto logout safter timeout.
Delivering an outstanding user experience with a modern, intuitive interface that minimizes learning curves and increases workflow confidence.
Easy-to-use because you can:
Video 1
Video 2
Optimizing lab performance with tableside touchscreen control, systems integration, data management and remote service diagnostics
Increase case efficiency, save time and reduce errors with seamless data
Image 1
Image 2
The IntraSight platform allows physicians to perform intravascular ultrasound (IVUS) imaging and physiologic measurements of fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) to accurately identify the location of lesions causing ischemia.
*Philips Mobile Interventional Applications Platform – IntraSight Mobile – is CE marked for sale in Europe and has received FDA 510(k) clearance for sale in the U.S. 1. Davies JE, et al., DEFINE-FLAIR: A Multi- Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR andFFR Decision-Making for Physiological Guided Coronary Revascularization. New England Journal of Medicine, epub March 18, 2017. 2. Gotberg M, et al., iFR-SWEDEHEART Investigators.. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-18233. 3. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision-making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018. 4. A. Maehara, M. Matsumura, Z.A. Ali, G.S. Mintz, G.W. Stone. IVUS-guided versus OCT-guided coronary stent implantation. J Am Coll Cardiol Img, 10 (2017), pp. 1487-1503. 5. Choi K, et al. Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing ComplexProcedures. JACC: Cardiovascular Interventions. Mar 2019, 4281; DOI: 10.1016/j.jcin.2019.01.227. 6. Co-registration tools available within IntraSight 7 configuration via SyncVision. 7. Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129. 8. 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96. 9. Lotfi, A., Davies, J. E., Fearon, W. F., Grines, C. L., Kern, M. J., & Klein, L. W. (2018). Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions, 92(2), 336–347. 10. Witzenbichler B, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: The ADAPT-DES study. Circulation. 2014 Jan:129,4;463-470.
How would you improve interventional procedures? What do you think about the new IntraSight Platform? Are we on the right track? Connect with us via #futureofIGT / IntraSight
#futureofIGT, #futureofCAD, #IntraSight, #CoronaryIntervention, #seeclearlytreatoptimally, #IVUS
You are about to visit a Philips global content page
Continue